Pfizer sues Teva for infringing Zyvox patent
WILMINGTON, Del. Jan 19 (Reuters) - Pfizer Inc (PFE.N) asked a U.S. federal court to block Teva Pharmaceutical Industries Ltd (TEVA.TA)TEVA.O from selling a generic form of its Zyvox antibiotic that it said would infringe a patent, according to court documents.
New York-based Pfizer asked the court for an injunction to prevent Israel's Teva from making or selling a generic version of Zyvox, according to the complaint filed on Friday in U.S. District Court in Delaware.
Zyvox, which is used to treat pneumonia and skin infections, has annual global sales of about $1.1 billion. The Teva generic would threaten Zyvox's U.S. sales, which totaled about $575 million.
Teva filed an abbreviated new drug application with the U.S. Food and Drug Administration, seeking approval to sell a generic version of Zyvox. Pfizer said the move infringed its patent.
Pfizer said in the complaint that its Zyvox patent would not expire until at least 2014.
Teva declined to comment.
Shares of Pfizer were up 2 percent at $19.89 in morning trading, while U.S.-traded shares of Teva rose 0.4 percent to $58.48.
The case is Pfizer Inc. et al v. Teva Parenteral Medicines Inc. et al, U.S. District Court, District of Delaware, No. 10-00037. (Reporting by Tom Hals; Editing by Lisa Von Ahn)
- White House reverses, says Obama met uncle and lived with him during law school
- Flights delayed as air pollution hits record in Shanghai
- South Africa mourns Mandela, will bury him on December 15 |
- Analysis: Boeing bidders dangle goodies to win 777X jetliner
- RPT-UPDATE 1-Ford leans on global Mustang to burnish overseas image